Press Releases

– If approved by the European Commission (EC), the label for EPIDYOLEX® will expand to include a third indication in Europe – LONDON, Feb. 26, 2021 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH) (“GW”, “the Company” or “the Group”), a world leader in discovering, developing and

– Total revenue of $148.2 million for the fourth quarter and $527.2 million for the full year – – Total Epidiolex ®  net product sales of $144.1 million for the fourth quarter and $510.5 million for the full year – – Previously announced agreement to be acquired by Jazz Pharmaceuticals; transaction

Adds high-growth commercial franchise to Neuroscience portfolio with Epidiolex®, the first and only FDA-approved prescription cannabidiol medicine and a potential near-term blockbuster Enhanced product diversification of combined company expected to provide accelerated double-digit revenue growth

- Total preliminary net product sales of approximately $148 million for the fourth quarter and approximately $526 million for the full year - - Total Epidiolex ®  preliminary net product sales of approximately $144 million for the fourth quarter and approximately $510 million for the full year – -

LONDON and CARLSBAD, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that Justin Gover, GW’s Chief Executive

EPIDIOLEX significantly reduced difficult-to-treat seizures, both focal and generalized CARLSBAD, Calif., Dec. 21, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of cannabinoid

LONDON and CARLSBAD, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that the Company will present at the Needham

- Meeting Highlights Include New Long-Term D ata in Tuberous Sclerosis Comple x - CARLSBAD, Calif., Dec. 01, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with U.S.

LONDON and CARLSBAD, Calif., Nov. 30, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that the Company will present at the Evercore

- Results from analysis of three P hase 3 clinical studies showed statistically significant improvement in spasticity in people with multiple sclerosis - Treatment with nabiximols seen in this analysis was not associated with increased muscle weakness or a notable change in preferred walking speed